LGI1: A GABA-rich Protein Involved in The Development of Neurological Disorders

Target Name: LGI1

NCBI ID: G9211

LGI1

LGI1: A GABA-rich Protein Involved in The Development of Neurological Disorders

LGI1 (Long GABA Interneuron 1) is a protein that is expressed in the brain and is known for its role in the development and maintenance of neural circuits. It is a GABA-rich protein that can interact with other GABA receptors, including GABAAR1 and GABAER2, to regulate the activity of neurons. LGI1 is also known as adenosine-A2A (A2A) receptor because it is a ligand for this receptor.

Recent studies have suggested that LGI1 may be a drug target for various neurological disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Its role in these disorders is not well understood, but it is known that LGI1 is involved in the regulation of neuronal activity and that abnormalities in its function may contribute to the development of these disorders.

One of the key features of LGI1 is its ability to interact with GABAAR1 and GABAER2, which are GABA receptors that are involved in the regulation of neuronal activity. GABAAR1 is a GABA receptor that is expressed in many different tissues, including the brain, and is known for its role in the regulation of muscle tone, anxiety, and pain. GABAER2 is a smaller GABA receptor that is also expressed in the brain and is involved in the regulation of neuronal activity.

Research has suggested that LGI1 may be involved in the regulation of GABAAR1 and GABAER2 activity because it is a known ligand for these receptors. Studies have shown that when LGI1 is expressed in neurons, it can interact with GABAAR1 and GABAER2 to regulate the activity of these receptors. This suggests that LGI1 may be a useful target for drugs that are designed to modulate the activity of these receptors.

Another potential mechanism by which LGI1 may be involved in the development of neurological disorders is its role in the regulation of neuronal communication. Neurons communicate with each other through the release and reception of chemical messengers called neurotransmitters, and the regulation of these messengers is critical for the function of the nervous system. LGI1 has been shown to be involved in the regulation of neurotransmitter release from neurons, and abnormalities in its function may contribute to the development of disorders such as Alzheimer's disease and Parkinson's disease.

In addition to its role in the regulation of GABAAR1 and GABAER2 activity, LGI1 is also known as adenosine-A2A (A2A) receptor because it is a ligand for this receptor. Adenosine is a natural compound that is involved in a variety of physiological processes, including the regulation of pain, inflammation, and sleep. The A2A receptor is a GABA-based receptor that is involved in the regulation of pain perception and other physiological processes.

The role of LGI1 in the regulation of A2A receptor activity is not well understood, but it is known that LGI1 can interact with this receptor to regulate its activity. Studies have shown that when LGI1 is expressed in cells, it can interact with A2A receptors to regulate the release of adenosine. This suggests that LGI1 may be a useful target for drugs that are designed to modulate the activity of A2A receptors.

Overall, LGI1 is a protein that is expressed in the brain and is involved in the regulation of a variety of physiological processes. Its role in the regulation of GABAAR1 and GABAER2 activity suggests that it may be a useful target for drugs that are designed to modulate the activity of these receptors. Its role in the regulation of neuronal communication and its involvement as an A2A receptor suggest that it may be a

Protein Name: Leucine Rich Glioma Inactivated 1

Functions: Regulates voltage-gated potassium channels assembled from KCNA1, KCNA4 and KCNAB1. It slows down channel inactivation by precluding channel closure mediated by the KCNAB1 subunit. Ligand for ADAM22 that positively regulates synaptic transmission mediated by AMPA-type glutamate receptors (By similarity). Plays a role in suppressing the production of MMP1/3 through the phosphatidylinositol 3-kinase/ERK pathway. May play a role in the control of neuroblastoma cell survival

The "LGI1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LGI1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets